Wave Life Sciences Ltd.WVEEarnings & Financial Report
BIT Life Sciences is a for profit meetings, incentives, conferencing, exhibitions (MICE) company based in Dalian, China, that specializes in arranging multiple scientific congresses that have been described as "predatory". The company is part of a wave of organizations that have appeared in China in the past several years noted for arranging congresses with little academic merit and with the primary aim of generating revenue rather than scientific knowledge sharing. Papers submitted are usual...
Revenue
$19.7M
Gross Profit
N/A
Operating Profit
$-35.0M
Net Profit
$-32.9M
Gross Margin
N/A
Operating Margin
-177.7%
Net Margin
-167.2%
YoY Growth
-10.9%
EPS
$-0.25
Wave Life Sciences Ltd. Q2 FY2024 Financial Summary
Wave Life Sciences Ltd. reported revenue of $19.7M (down 10.9% YoY) for Q2 FY2024, with a net profit of $-32.9M (down 56.0% YoY) (-167.2% margin).
Key Financial Metrics
| Total Revenue | $19.7M |
|---|---|
| Net Profit | $-32.9M |
| Gross Margin | N/A |
| Operating Margin | -177.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Wave Life Sciences Ltd. Q2 FY2024 revenue of $19.7M breaks down across 2 segments, led by Gsk Collaboration Agreement at $19.1M (97.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Gsk Collaboration Agreement | $19.1M | 97.0% |
| Other | $592.0K | 3.0% |
Wave Life Sciences Ltd. Revenue by Segment — Quarterly Trend
Wave Life Sciences Ltd. revenue by segment across the last 4 reported quarters, showing how each business line (such as Gsk Collaboration Agreement and Other) has evolved quarter over quarter.
| Segment | Q2 FY2025 | Q1 FY2025 | Q2 FY2024 | Q1 FY2024 |
|---|---|---|---|---|
| Gsk Collaboration Agreement | $8.7M | $9.2M | $19.1M | — |
| Other | — | — | $592.0K | — |
Wave Life Sciences Ltd. Annual Revenue by Year
Wave Life Sciences Ltd. annual revenue history includes year-by-year totals (for example, 2023 revenue was $113.3M).
| Year | Annual Revenue |
|---|---|
| 2023 | $113.3M |
Wave Life Sciences Ltd. Quarterly Revenue & Net Profit History
Wave Life Sciences Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $8.7M | -55.8% | $-50.5M | -580.2% |
| Q1 FY2025 | $9.2M | -26.8% | $-46.9M | -510.9% |
| Q2 FY2024 | $19.7M | -10.9% | $-32.9M | -167.2% |
| Q1 FY2024 | $12.5M | -3.0% | $-31.6M | -251.7% |
| Q4 FY2023 | $29.1M | +2245.1% | $-16.3M | -55.9% |
| Q3 FY2023 | $49.2M | +17168.1% | $7.3M | 14.7% |
| Q2 FY2023 | $22.1M | +5794.9% | $-21.1M | -95.5% |
| Q1 FY2023 | $12.9M | +638.8% | $-27.4M | -212.0% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.9M | $22.1M | $49.2M | $29.1M | $12.5M | $19.7M | $9.2M | $8.7M |
| YoY Growth | 638.8% | 5794.9% | 17168.1% | 2245.1% | -3.0% | -10.9% | -26.8% | -55.8% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $267.3M | $230.0M | $199.9M | $274.9M | $235.3M | $208.8M | $288.3M | $252.4M |
| Liabilities | $294.1M | $273.8M | $232.5M | $227.4M | $202.0M | $204.4M | $108.7M | $105.2M |
| Equity | $-34.7M | $-51.7M | $-40.5M | $39.6M | $25.4M | $-3.5M | $171.8M | $139.3M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $85.5M | $-37.3M | $-34.5M | $-33.2M | $-33.4M | $-27.5M | $-63.0M | $-46.0M |